Marjolein van der Klift
Overview
Explore the profile of Marjolein van der Klift including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ekels A, van de Poll-Franse L, Issa D, Hoogendoorn M, Nijziel M, Koster A, et al.
Ann Hematol
. 2024 Sep;
103(12):5511-5525.
PMID: 39279019
With the increasing prevalence of comorbidity in an ageing population, it is crucial to better understand the impact of comorbidity on health-related quality of life (HRQoL) after lymphoma or multiple...
2.
van der Straten L, Stege C, Kersting S, Nasserinejad K, Dubois J, Dobber J, et al.
Blood
. 2023 Jun;
142(13):1131-1142.
PMID: 37363833
Chronic lymphocytic leukemia (CLL)-related symptoms and morbidity related to the advanced age at diagnosis impairs the well-being of older adult patients. Therefore, it is essential to tailor treatment according to...
3.
Bennink C, Westgeest H, Schoonen D, Boersen F, Sonneveld P, Hazelzet J, et al.
Hemasphere
. 2023 Jun;
7(6):e913.
PMID: 37304934
No abstract available.
4.
Eichhorst B, Niemann C, Kater A, Furstenau M, von Tresckow J, Zhang C, et al.
N Engl J Med
. 2023 May;
388(19):1739-1754.
PMID: 37163621
Background: Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have...
5.
Bennink C, de Mul M, van der Klift M, Broijl A, Tick L, de Jongh E, et al.
Patient
. 2023 Feb;
16(3):255-264.
PMID: 36790557
Background And Objective: Multiple myeloma is an incurable disease with a considerable illness and treatment burden, which negatively impacts patients' quality of life. This study aimed to evaluate the implementation...
6.
Raa D, van der Straten L, van Gelder M, Kersting S, Levin M, Mous R, et al.
Leuk Lymphoma
. 2022 Jun;
63(10):2276-2289.
PMID: 35737364
Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future....
7.
Brink M, Minnema M, Visser O, Levin M, Posthuma E, Broijl A, et al.
Blood Cancer J
. 2022 Mar;
12(3):41.
PMID: 35292622
No abstract available.
8.
Kersting S, Dubois J, Nasserinejad K, Dobber J, Mellink C, van der Kevie-Kersemaekers A, et al.
Lancet Haematol
. 2022 Mar;
9(3):e190-e199.
PMID: 35240075
Background: Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles...
9.
Gharbharan A, GeurtsvanKessel C, Jordans C, Blaauw M, van der Klift M, Hassing R, et al.
Clin Infect Dis
. 2021 Jul;
74(7):1271-1274.
PMID: 34293119
Twenty-five B-cell-depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent...
10.
Bennink C, van der Klift M, Scheurer H, Sonneveld P, Duijts S
Eur J Cancer Care (Engl)
. 2021 Jun;
30(6):e13481.
PMID: 34152665
Objective: Multiple myeloma (MM) is a rare and incurable disease. Because new treatments improved survival rates, return to work (RTW) became more relevant to MM patients of working age. Also,...